Tokio Marine Asset Management Co. Ltd. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Tokio Marine Asset Management Co. Ltd. grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,227 shares of the biopharmaceutical company’s stock after buying an additional 206 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $3,392,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. International Assets Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Capital International Investors increased its holdings in Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares in the last quarter. Swedbank AB bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $129,257,000. Finally, Epoch Investment Partners Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $99,667,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on REGN. TD Cowen upped their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Barclays cut their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,097.14.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded down $5.65 during midday trading on Thursday, reaching $798.68. The company’s stock had a trading volume of 61,979 shares, compared to its average volume of 522,000. Regeneron Pharmaceuticals, Inc. has a one year low of $784.96 and a one year high of $1,211.20. The company has a market cap of $87.77 billion, a price-to-earnings ratio of 19.90, a price-to-earnings-growth ratio of 3.10 and a beta of 0.15. The company has a 50 day moving average price of $1,000.06 and a 200 day moving average price of $1,035.67. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.48% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.